SYRE peer analysis
Spyre Therapeutics (SYRE) against its competitors: price, today's move, 1-year return and market value side by side.
SYRE and its peers
| Company | Price | Today | 1-year return | Market cap |
|---|---|---|---|---|
| ABVX Abivax | $85.75 | 1.87% | -15.67% | $7.83B |
| ACRS Aclaris Therapeutics | $3.90 | 8.03% | 59.73% | $570.34M |
| AGMB AgomAb | $6.97 | 1.75% | – | – |
| ANAB AnaptysBio | $45.80 | 0.48% | 26.61% | $1.42B |
| ARDX Ardelyx | $2.85 | -4.68% | -49.58% | $827.02M |
| IFRX InflaRx | $1.30 | -3.69% | -4.03% | $218.10M |
| IMUX Immunic | $7.64 | 4.37% | 1.26% | $108.34M |
| ODTX Odyssey Therapeutics | $19.23 | 1.85% | – | – |
| UPB Upstream Bio | $3.21 | 0.16% | -86.61% | – |
| SYRE Spyre Therapeutics | $103.00 | 6.64% | 322.71% | – |
- SYRE's peers: ABVX (Abivax), ACRS (Aclaris Therapeutics), AGMB (AgomAb), ANAB (AnaptysBio), ARDX (Ardelyx), IFRX (InflaRx), IMUX (Immunic), ODTX (Odyssey Therapeutics).
Updated 2026-11-07 11:55 UTC